Status:
UNKNOWN
Clinical Application of an Automated Liquid Biopsy Platform for Early Detection of Colorectal Cancer
Lead Sponsor:
CellMaxLife
Conditions:
Colo-rectal Cancer
Eligibility:
All Genders
20+ years
Brief Summary
Colorectal cancer (CRC) is among the most preventable cancers when precancerous lesions are detected at an early stage. Current screening methods for CRC require bowel prep or stool-based testing that...
Detailed Description
1. Selection of patients: A. The disease group includes 300 patients diagnosed with stages 0-4 colorectal cancer not previously treated. B. The control group includes 450 control subjects who ...
Eligibility Criteria
Inclusion
- 1\. The disease group is diagnosed with colorectal cancer 0-4 and has not been treated.
- 2\. The control group will receive Colonoscopy
- 3\. Above 20 years old
Exclusion
- 1\. Refuse to sign the informed consent form
- 2\. Received surgery within one month
- 3\. Previous cancer history
- 4\. Autoimmune diseases
- 5\. Chronic inflammatory diseases
- 6\. Acute inflammatory or infectious diseases in three months
- 7\. Myelodysplastic syndromes and myeloproliferative disorder
- 8\. Other diseases decided by PI
Key Trial Info
Start Date :
March 15 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 13 2021
Estimated Enrollment :
750 Patients enrolled
Trial Details
Trial ID
NCT03476122
Start Date
March 15 2018
End Date
March 13 2021
Last Update
April 2 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Linkou Chang Gung Memorial Hospital
Taoyuan, Taiwan